Table 4.

Clinical information and treatment outcomes of six patients who received EGFR TKIs

Sex	Age (yr)	Exon 20 type	ECOG	Smoking history	Initial stage	TKI type	EGFR TKI response	PFS
F	44	Insertion	1	Never-smoker	IV	Erlotinib	PD	0.7
M	65	Insertion	2	Never-smoker	IV	Afatinib	PD	0.9
M	60	Insertion	1	Current smoker 30PY	IV	Erlotinib	PD	2.6
M	48	Insertion	0	Ex-smoker 20PY	IV	Erlotinib	SD	11.4
M	62	Insertion+L858R	1	Ex-smoker 10PY	IIB	Afatinib	PR	1.9
F	43	Insertion+G719S	1	Never-smoker	IV	Osimertinib	PR	2.8

EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free survival; F, female; M, male; PD, progressive disease; SD, stable disease; PR, partial response.